Health expects Novavax’s Covid vaccine to be authorized in April

The antigen, which will be manufactured in the Galician Biofabri plant, has shown an efficacy of 89% against the coronavirus.

The Minister of Health, Carolina Darias, visited the Biofabri plant of the Zendal biopharmaceutical group this Thursday, where the Novavax Covid vaccine is manufactured, and has affirmed that, if there are no problems, will be authorized “as of April” by the European Medicines Agency (EMA).

Darias has transferred the “support” of the Government to the work carried out in this plant, the first Spanish company to fully manufacture a vaccine against the coronavirus.

In this regard, he recalled that this vaccine is already being evaluated by the EMA and the Government of Spain hopes that, after Jansen’s, “it will be the next vaccine that would have the authorization of the EMA”.

In addition, he stressed that the clinical trials of this vaccine have shown “promising results”, even in the face of some of the new variants, such as the South African one. “That it takes place here, in O Porriño (Pontevedra), supposes to place Spain in a tremendously powerful position in the rest of the European context and also at an international level ”, has had an impact.

On the other hand, the CEO of Zendal, Andrés Fernández, has also referred to the other vaccines, the ‘Spanish’ ones, in which the O Porriño plant works, in cooperation with the CSIC.

Specifically, he has referred to the one that is more advanced and led by Mariano Esteban and Juan García Arriaza, and has indicated that clinical trials will begin soon.